We deserve clarity, understanding, and equitable healthcare from the very beginning.
For generations, a condition affecting 170 million women worldwide was named for something it does not actually cause — a quiet but consequential error that shaped how medicine listened, or failed to listen, to those who carried it. This week, polycystic ovary syndrome became polyendocrine metabolic ovarian syndrome, a renaming that is less a rebrand than a reckoning: an acknowledgment that language shapes care, and that inaccurate language can quietly harm. Led by Australian endocrinologist Professor Helena Teede and guided by the voices of affected women across cultures, the change marks a rare moment when science, advocacy, and accountability converge in the service of those long underserved.
- Decades of misdiagnosis and fragmented care were quietly sustained by a name that pointed doctors toward ovaries while the real disorder — hormonal and metabolic in nature — went underappreciated and undertreated.
- The scientific ground finally gave way entirely when research confirmed that women with the condition show no higher rates of abnormal ovarian cysts than unaffected women, making the old name not just imprecise but indefensible.
- Professor Helena Teede led an internationally collaborative, culturally sensitive renaming process designed to serve patients first — ensuring the new name, PMOS, carries scientific accuracy without importing new stigmas across diverse languages and contexts.
- A three-year transition beginning now will carry the new name into clinical practice, research frameworks, and medical education, with full integration into the 2028 International Guideline update.
- For the millions of women who spent years undiagnosed or misunderstood, the renaming is arriving as both vindication and promise — a signal that the medical world is, at last, beginning to see the full picture.
A condition affecting 170 million women worldwide has finally been given a name that reflects what it actually is. Polycystic ovary syndrome — PCOS — is now officially polyendocrine metabolic ovarian syndrome, or PMOS. Announced at the European Congress of Endocrinology and published in The Lancet, the change is the result of more than a decade of work by researchers, clinicians, and patients who understood that the old name was doing real harm.
The damage was embedded in the language itself. By centering cysts and ovaries, PCOS framed a systemic hormonal and metabolic disorder as a reproductive one. Women arrived at clinics with mood disorders, metabolic struggles, and skin conditions only to receive fragmented care aimed at the wrong target. The case for change became irrefutable when research showed that women with the condition do not actually have elevated rates of abnormal ovarian cysts — the foundational premise of the old name was simply wrong.
Australian endocrinologist Professor Helena Teede, who has spent decades studying the condition and witnessing its toll, led the international effort to rename it. The process was deliberately inclusive, consulting across cultures to ensure the new name would not trade one form of stigma for another. The guiding principles were scientific accuracy, patient benefit, ease of communication, and cultural appropriateness — a renaming done with affected women, not merely about them.
Lorna Berry, an Australian woman living with the condition who participated in the initiative, captured what the moment means: "This is about my daughters, their daughters, and the countless women yet to be born. We deserve clarity, understanding, and equitable healthcare from the very beginning."
A three-year transition period is now underway, with the new name formally embedded in the 2028 International Guideline update. Clinicians, researchers, and medical students will learn to speak differently about this condition — and the hope is that speaking more truthfully will mean diagnosing more quickly, treating more completely, and finally giving PMOS the research attention it has long been denied.
A condition that has shadowed the lives of 170 million women worldwide—causing irregular periods, weight struggles, skin problems, mood disorders, and fertility challenges—finally has a name that matches what it actually is. Polycystic ovary syndrome, known for decades as PCOS, is now officially polyendocrine metabolic ovarian syndrome, or PMOS. The shift, announced this week at the European Congress of Endocrinology and published in The Lancet, represents more than semantic housekeeping. It is the culmination of over a decade of advocacy by researchers, clinicians, and patients who watched the old name do real damage.
The problem was always there in the language itself. PCOS—with its emphasis on cysts and ovaries—reduced a systemic hormonal disorder to a reproductive issue. Women came to doctors with metabolic problems, mental health struggles, and skin conditions, only to be told these were side effects of an ovarian problem. The diagnosis was delayed. The care was fragmented. The stigma was real. Then came the research that made the old name indefensible: women with the condition did not actually have higher rates of abnormal ovarian cysts than women without it. The foundational premise was wrong.
Australian endocrinologist Professor Helena Teede, director of the Monash Centre for Health Research and Implementation, led the push for change. She had spent decades studying the condition and witnessing its toll on patients—the heartbreak of delayed diagnosis, the inadequate treatment, the sense that the medical system did not fully grasp what was happening to their bodies. "What we now know," Teede said, "is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated." The new name reflects the reality: this is a disorder of hormones and metabolism that happens to involve the ovaries, not a disease of the ovaries themselves.
The renaming process was deliberately inclusive. Teede and her international collaborators, including Professor Terhi Piltonen of the International Androgen Excess and Polycystic Ovary Syndrome Society, consulted across cultures and contexts. Some languages and regions carry particular stigma around reproductive terminology; the new name had to work globally without deepening shame or harm. The principles guiding the change were patient benefit, scientific accuracy, ease of communication, avoidance of stigma, and cultural appropriateness. It was a renaming done with and for the women affected by the condition, not imposed upon them.
Lorna Berry, an Australian woman living with the condition and part of the renaming initiative, framed what is at stake. "This is about accountability and progress," she said. "It is about my daughters, their daughters, and the countless women yet to be born. We deserve clarity, understanding, and equitable healthcare from the very beginning." The words carry the weight of delayed diagnoses, of symptoms dismissed, of years spent not understanding one's own body.
Implementation will unfold gradually. A three-year transition period begins now, with the new name formally integrated into the 2028 International Guideline update. Clinicians will shift their language. Researchers will reframe their work. Medical students will learn PMOS, not PCOS. The hope is that with a name that finally tells the truth, diagnosis will come faster, treatment will be more comprehensive, and the condition will receive the research funding and clinical attention it has long deserved. For millions of women who have lived with this condition in the shadows of a misleading name, the change signals that the medical world is finally listening.
Citas Notables
What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated.— Professor Helena Teede
This is about accountability and progress. We deserve clarity, understanding, and equitable healthcare from the very beginning.— Lorna Berry, woman with PMOS and renaming initiative participant
La Conversación del Hearth Otra perspectiva de la historia
Why did it take so long to change the name? The science seems straightforward—no excess cysts, so the name is wrong.
Because names stick. They become embedded in medical training, in how doctors think about a condition, in how patients understand themselves. Changing a name means changing how an entire profession thinks. That takes consensus, evidence, and time.
But what was the actual harm of the old name beyond just being inaccurate?
It narrowed the lens. Women came in with metabolic problems—weight gain, insulin resistance, mood issues—and were told these were secondary to an ovarian problem. The real disorder, the systemic hormonal imbalance, was invisible. Diagnosis was delayed. Care was fragmented. And there's the stigma: being told you have a reproductive disorder when you're struggling with depression or acne or infertility.
So the new name—PMOS—it's not just more accurate. It's also supposed to reduce shame?
Yes. Reproductive terminology carries different weight in different cultures. Some regions have deep stigma around ovarian or fertility-related conditions. The new name is more clinical, more metabolic. It describes what's actually happening without triggering that same cultural baggage.
What changes for a patient on day one after implementation?
Probably nothing immediate. But over time, faster diagnosis. Better coordination between endocrinologists and gynecologists. Research funding directed at metabolic and hormonal aspects, not just fertility. And for young women being diagnosed now, it means understanding from the start that this is a whole-body condition, not just an ovarian one.
Lorna Berry said this is for her daughters and granddaughters. Does that suggest the current generation of women with PCOS feels left behind?
Absolutely. They've lived with a misnamed condition, often undiagnosed for years, sometimes told their symptoms were in their head. The name change won't retroactively give them better care, but it signals that the system finally sees them clearly.